Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04985916 · ClinicalTrials.gov registry record · Phase 2
ET-01 in Subjects With Lateral Canthal Lines, LCL-210
A Phase 2 study, sponsored by Eirion Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 280
- Enrollment target
NCT04985916 is a Phase 2 study that has completed, run by Eirion Therapeutics. The registered enrollment target is 280 participants.
The verdict
NCT04985916, a Phase 2 study, has completed, sponsored by Eirion Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 280 participants
- Enrollment target
Study Summary
This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).
Interventions
- BIOLOGICAL Vehicle
- BIOLOGICAL botulinum toxin, Type A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2021-07-19 |
| Est. Completion | 2024-02-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04985916
The ClinicalTrials.gov registry entry for NCT04985916 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 280 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eirion Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT04985916 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04985916 about?
NCT04985916 is a clinical study titled "ET-01 in Subjects With Lateral Canthal Lines, LCL-210". This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).
What is the current status of trial NCT04985916?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 280 participants. The study started on 2021-07-19. Estimated completion is 2024-02-08.
What interventions are being tested in trial NCT04985916?
The interventions under investigation include: Vehicle (BIOLOGICAL), botulinum toxin, Type A (BIOLOGICAL).
Who is sponsoring clinical trial NCT04985916?
This trial is sponsored by Eirion Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.